semaglutide empagliflozin Ozempic outperforms another diabetes drug for reducing stroke risk Separate and combined effects of

This combination leverages the synergistic benefits of both peptides while maintaining individual safety standards under medical supervision

However, in order to do so, we will need, from time to time, to notify or make submissions with regulatory authorities, and the improvements may be subject to approval by such regulatory authorities

The TRIUMPH-1 trial, which focuses on core obesity management, is expected to read out in mid-2026

Previously, the only way a Medicare patient could access semaglutide was if they had a type 2 diabetes diagnosis, in which case their doctor could prescribe Ozempic (semaglutide at the 0.5 mg, 1 mg, or 2 mg dose approved for diabetes)

Final Takeaway The before and after results speak for themselves